The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Etiologic Diagnosis of Ischemic Stroke Subtypes With Plasma Biomarkers
Abstract
Background and Purpose— Because there is no biologic marker offering precise information about stroke etiology, many patients receive a diagnosis of undetermined stroke even after all available diagnostic tests are done, precluding correct treatment. Methods— To examine the diagnostic value of a panel of biochemical markers to differentiate stroke etiologies, consecutive acute stroke patients were prospectively evaluated. Brain computed tomography, ultrasonography, cardiac evaluations, and other tests were done to identify an etiologic diagnosis according to TOAST classification. Blood samples were drawn on Emergency Department arrival (<24 hours) to test selected biomarkers: C-reactive protein, D-dimer, soluble receptor for advanced glycation end products, matrix metalloproteinase-9, S-100b, brain natriuretic peptide (BNP), neurotrophin-3, caspase-3, chimerin, and secretagogin (assayed by ELISA). Results— Of 707 ischemic stroke patients included, 36.6% were cardioembolic, 21.4% atherothrombotic, 18.1% lacunar, and 23.9% of undetermined origin. High levels of BNP, soluble receptor for advanced glycation end products, and D-dimer ( P <0.0001) were observed in patients with cardioembolic stroke. Independent predictors (odds ratios with CIs are given) of cardioembolic stroke were as follows: atrial fibrillation 15.3 (8.4–27.7, P <0.001); other embolic cardiopathies 14.7 (4.7–46, P <0.001); total anterior circulation infarction 4 (2.3–6.8, P <0.001); BNP >76 pg/mL 2.3 (1.4–3.7, P =0.001); and D-dimer >0.96 μg/mL 2.2 (1.4–3.7, P =0.001). Even among patients with transient symptoms (n=155), a high BNP level identified cardioembolic etiology (6.7, 2.4–18.9; P <0.001). A model combining clinical and biochemical data had a sensitivity of 66.5% and a specificity of 91.3% for predicting cardioembolism. Conclusions— Using a combination of biomarkers may be a feasible strategy to improve the diagnosis of cardioembolic stroke in the acute phase, thus rapidly guiding other diagnostic tests and accelerating the start of optimal secondary prevention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kolominsky-Rabas, P. L., Weber, M., Gefeller, O., Neundoerfer, B., & Heuschmann, P. U. (2001) · Stroke · doi:10.1161/hs1201.100209 · Cited by 1,281
Cited by
Turner, R. J., & Sharp, F. R. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00056 · Cited by 533
Blood Markers for the Prognosis of Ischemic Stroke: A Systematic Review
Whiteley, W., Chong, W. L., Sengupta, A., & Sandercock, P. (2009) · Stroke · doi:10.1161/strokeaha.108.528752 · Cited by 290
Matrix Metalloproteinase-9 as a Marker for Acute Ischemic Stroke: A Systematic Review
Ramos-Fernandez, M., Bellolio, M. F., & Stead, L. G. (2011) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2009.10.008 · Cited by 220
Maillard-Lefebvre, H., Boulanger, E., Daroux, M., Gaxatte, C., Hudson, B. I., & Lambert, M. (2009) · Rheumatology · doi:10.1093/rheumatology/kep199 · Cited by 190
Metadata
- Authors
- Montaner, J., Perea-Gainza, M., Delgado, P., Ribó, M., Chacón, P., Rosell, A., Quintana, M., Palacios, M. E., Molina, C. A., & Alvarez-Sabín, J.
- Venue
- Stroke
- Published
- 2008-08
- Volume
- 39
- Issue
- 8
- Pages
- 2280-2287
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2161212353
- Cited by
- 303
- References
- 1
- FWCI
- 15.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Etiologic Diagnosis of Ischemic Stroke Subtypes With Plasma Biomarkers. https://app.cochat.ai/papers/10.1161/strokeaha.107.505354
- The paper
- Montaner, J., Perea-Gainza, M., Delgado, P., Ribó, M., Chacón, P., Rosell, A., Quintana, M., Palacios, M. E., Molina, C. A., & Alvarez-Sabín, J. (2008). Etiologic Diagnosis of Ischemic Stroke Subtypes With Plasma Biomarkers. Stroke. https://doi.org/10.1161/strokeaha.107.505354
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.